⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12259 | 0.97 | — | — | |
| SCHEMBL5252 | 0.97 | CYP1A2 (0.40) | — | |
| SCHEMBL7738618 | 0.97 | CYP1A2 (0.40) | — | |
| SCHEMBL11224706 | 0.97 | CYP1A2 (0.40) | — | |
| SCHEMBL5495 | 0.97 | CYP1A2 (0.40) | — | |
| SCHEMBL7739283 | 0.97 | CYP1A2 (0.40) | — | |
| SCHEMBL5244 | 0.94 | — | — | |
| Methyl Alcohol SCHEMBL10396919 | 0.92 | LMNA (0.41) | — | |
| SCHEMBL9349823 | 0.87 | CYP1A2 (0.44) | — | |
| SCHEMBL22454265 | 0.87 | CTSL (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 422 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526223-B1 | METHOD FOR ISOLATION AND PURIFICATION OF NALTREXONE | SANECA PHARMACEUTICALS A S (SK) | 2021-03-17 | — | — | EP | claimed |
| EP-2782938-A1 | HIGH ACTIVITY CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND METHOD OF USING THE SAME | BASF Corporation (US) | 2014-10-01 | — | — | EP | claimed |
| WO-2013077837-A1 | HIGH ACTIVITY CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND METHOD OF USING THE SAME | BASF CORPORATION (US) | 2013-05-30 | — | — | WO | claimed |
| US-20090221596-A1 | Substtituted aryl oximes | BAYER CROPSCIENCE AG (DE) | 2009-09-03 | — | — | US | claimed |
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | claimed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | claimed |
| US-20090042957-A1 | Substituted Oxyarenes | BAYER CROPSCIENCE AG (DE) | 2009-02-12 | — | — | US | claimed |
| EP-1883622-A1 | SUBSTITUTED ARYL OXIMES | Bayer CropScience Aktiengesellschaft (DE) | 2008-02-06 | — | — | EP | claimed |
| EP-1831145-A1 | SUBSTITUTED OXYARENES | Bayer CropScience Aktiengesellschaft (DE) | 2007-09-12 | — | — | EP | claimed |
| WO-2007090434-A1 | SUBSTITUTED ARYL OXIMES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2007-08-16 | — | — | WO | claimed |
| WO-2006069685-A1 | SUBSTITUTED OXYARENES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2006-07-06 | — | — | WO | claimed |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-11-10 | — | — | US | claimed |
| EP-1528925-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2005-05-11 | — | — | EP | claimed |
| WO-2004004732-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | claimed |
| EP-0532178-B1 | Methanoanthracenes as dopamine antagonists | ZENECA LTD (GB) | 1996-10-16 | — | — | EP | claimed |
| US-5266570-A | Neuropsychiatric disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-11-30 | — | — | US | claimed |
| EP-0532178-A1 | Methanoanthracenes as dopamine antagonists | ZENECA LIMITED (GB) | 1993-03-17 | — | — | EP | claimed |
| EP-4400561-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2024-07-17 | — | — | EP | disclosed |
| US-4246402-A | CARDIOVASCULAR AGENTS AND OXYTOCICS | HOFFMANN-LA ROCHE INC. (US) | 1981-01-20 | — | — | US | disclosed |
| US-4036871-A | CARDIOVASCULAR AGENTS, LABOR INDUCERS, ABORTION | HOFFMANN-LA ROCHE INC. (US) | 1977-07-19 | — | — | US | disclosed |